Related Experiment Video

Updated: Jun 2, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

[The design of muti-target antitumor drugs affecting on FTase and Raf-1 kinase]

Juan Zhao1, Yi-jing Zhu, Lu Zeng

  • 1School of Pharmacy, Tong]i Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|May 6, 2011
PubMed

Insights

Researchers designed novel aminomethylbenzoic acid derivatives as potential inhibitors for farnesyl transferase (FTase) and Raf-1 kinase. This study utilized computer-aided drug design to create pharmacophore models for targeted drug discovery in cell signaling pathways.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Pharmacology

Context:

  • The Ras/Raf/MEK/ERK signaling pathway is crucial for cellular processes like proliferation, differentiation, apoptosis, and metastasis.
  • Dysregulation of this pathway is implicated in various diseases, necessitating targeted therapeutic interventions.

Purpose:

  • To identify novel inhibitors targeting farnesyl transferase (FTase) and Raf-1 kinase within the Ras/Raf/MEK/ERK pathway.
  • To develop pharmacophore models for FTase inhibitors (FTIs) and Raf-1 kinase inhibitors using computer-aided drug design (CADD).

Summary:

  • Pharmacophore models for FTase inhibitors (hydrogen bonding acceptor, aromatic ring, positive ionizable, two hydrophobic regions) and Raf-1 kinase inhibitors (hydrogen donor, hydrogen acceptor, hydrophobic region, aromatic ring) were constructed.
  • Analysis revealed similarities between the two pharmacophore models.
  • New aminomethylbenzoic acid derivatives were designed based on these models, exhibiting predicted activity against both FTase and Raf-1 kinase.

Impact:

  • This research provides a foundation for developing new small molecules targeting key components of the Ras/Raf/MEK/ERK pathway.
  • The designed compounds hold potential for therapeutic applications in diseases driven by aberrant cell signaling.
  • The study demonstrates the utility of CADD in accelerating the discovery of multi-target inhibitors.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...